Nasal Spray With Glucose Oxidase Preventing Common Cold in Pre-school Children
Primary Purpose
Upper Respiratory Tract Infections
Status
Completed
Phase
Phase 2
Locations
Sweden
Study Type
Interventional
Intervention
Placebo
Glucose oxidase
Sponsored by
About this trial
This is an interventional treatment trial for Upper Respiratory Tract Infections focused on measuring Days with URTI symptoms
Eligibility Criteria
Inclusion Criteria:
- Children below 4 years of age
Exclusion Criteria:
- None
Sites / Locations
- Öronmottagningen
- Öronmottagningen
- Öronmottagningen
- Öronmottagningen
Arms of the Study
Arm 1
Arm 2
Arm Type
Placebo Comparator
Active Comparator
Arm Label
Placebo: Saline+glucose nasal spray
Nasal spray with glucose oxidase+glucose
Arm Description
Subjects received nasal spray containing both saline+glucose twice daily for 3 months
Nasal spray in a bag-on-valve device with 50U/ml containing both glucose oxidase + 5% glucose in isotone saline. Dosage: One puff in each nostril twice daily for 3 months.
Outcomes
Primary Outcome Measures
Respiratory Infectious Symptoms
Days with upper respiratory tract infection symptoms during a 3 months period are recorded in a home protocol by the parents of the children.
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01883427
Brief Title
Nasal Spray With Glucose Oxidase Preventing Common Cold in Pre-school Children
Official Title
Placebo Controlled Study Among Children Below Four Years of Age, Investigating Whether a Glucose Oxidase Nasal Spray Can Reduce Days With Upper Respiratory Tract Infection Symptoms
Study Type
Interventional
2. Study Status
Record Verification Date
December 2015
Overall Recruitment Status
Completed
Study Start Date
October 2012 (undefined)
Primary Completion Date
May 2013 (Actual)
Study Completion Date
June 2013 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Krister Tano
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
To investigate if use of glucosoxidas nasal spray can reduce the number of days with upper respiratory tract infections in children beyond 4 years.
Detailed Description
Children below 4 years of age and in public day care were invited to participate in this prospective study. The children started with a visit to an ENT doctor and after inclusion the children started to spray twice daily with glucose oxidase+glucose or only saline+glucose for 3 months. During this period the parents were asked to fill in a home protocol recording upper respiratory tract symptoms as: rhinitis, cough, fever, ear ache. After 6 weeks and 12 weeks the children had scheduled visits to the ENT department, where an ENT doctor examined the throat, nasal cavity and the ear drums for otitis media. After 12 weeks of treatment a nasopharyngeal swab was taken for bacterial culture.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Upper Respiratory Tract Infections
Keywords
Days with URTI symptoms
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
40 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Placebo: Saline+glucose nasal spray
Arm Type
Placebo Comparator
Arm Description
Subjects received nasal spray containing both saline+glucose twice daily for 3 months
Arm Title
Nasal spray with glucose oxidase+glucose
Arm Type
Active Comparator
Arm Description
Nasal spray in a bag-on-valve device with 50U/ml containing both glucose oxidase + 5% glucose in isotone saline. Dosage: One puff in each nostril twice daily for 3 months.
Intervention Type
Drug
Intervention Name(s)
Placebo
Other Intervention Name(s)
Baxter Rehydrex
Intervention Description
placebo containing saline+glucose
Intervention Type
Drug
Intervention Name(s)
Glucose oxidase
Other Intervention Name(s)
G2133, Sigmaaldrich
Intervention Description
a hydrogen peroxide producing enzyme that creates an acidous environment to which rhinoviruses are sensitive.
Primary Outcome Measure Information:
Title
Respiratory Infectious Symptoms
Description
Days with upper respiratory tract infection symptoms during a 3 months period are recorded in a home protocol by the parents of the children.
Time Frame
3 months of recording
10. Eligibility
Sex
All
Maximum Age & Unit of Time
3 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Children below 4 years of age
Exclusion Criteria:
None
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Eva Westman, MD, PhD
Organizational Affiliation
Västernorrlands Landsting
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Marie Ryding, MD, PhD
Organizational Affiliation
Jämtlands Landsting
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Anders Niklasson, MD
Organizational Affiliation
Norrbottens Landsting
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Helena Toolanen, MD
Organizational Affiliation
Norrbottens Landsting
Official's Role
Study Chair
Facility Information:
Facility Name
Öronmottagningen
City
Piteå
Country
Sweden
Facility Name
Öronmottagningen
City
Sunderbyn
Country
Sweden
Facility Name
Öronmottagningen
City
Sundsvall
Country
Sweden
Facility Name
Öronmottagningen
City
Östersund
Country
Sweden
12. IPD Sharing Statement
Learn more about this trial
Nasal Spray With Glucose Oxidase Preventing Common Cold in Pre-school Children
We'll reach out to this number within 24 hrs